Potassium clorazepate (Tranxene)-induced jaundice.
A first report of jaundice and hepatic necrosis probably due to potassium clorazepate is described. The histology is discussed and it is suggested that the drug should not be given in the presence of suspected hepatic dysfunction.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D003009:Clorazepate Dipotassium / Q000009:adverse effects*; D006801:Humans; D007565:Jaundice / Q000139:chemically induced* / Q000473:pathology; D008099:Liver / Q000473:pathology; D008297:Male; D009336:Necrosis
D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium